2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 528.454 | 408.218 | 435.733 | 440.377 | 290.856 | 296.655 | 347.054 | 470.619 | 442.093 | 756.203 |
Total Income - EUR | 499.424 | 408.422 | 435.888 | 440.524 | 298.261 | 299.772 | 347.054 | 470.874 | 444.603 | 756.203 |
Total Expenses - EUR | 453.502 | 353.961 | 443.373 | 416.011 | 255.005 | 294.179 | 336.898 | 456.698 | 496.189 | 700.575 |
Gross Profit/Loss - EUR | 45.923 | 54.461 | -7.484 | 24.513 | 43.256 | 5.593 | 10.156 | 14.176 | -51.587 | 55.629 |
Net Profit/Loss - EUR | 36.177 | 43.318 | -9.358 | 19.714 | 40.266 | 2.559 | 6.685 | 9.561 | -56.253 | 45.947 |
Employees | 16 | 21 | 25 | 18 | 15 | 12 | 13 | 15 | 13 | 12 |
Check the financial reports for the company - Izoprim S.r.l.
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 44.330 | 60.165 | 54.758 | 36.864 | 39.776 | 34.632 | 49.416 | 59.668 | 93.227 | 142.651 |
Current Assets | 78.025 | 50.289 | 67.677 | 37.640 | 67.431 | 53.091 | 78.638 | 167.239 | 44.892 | 288.868 |
Inventories | 0 | 0 | 0 | 0 | 17.740 | 832 | 9.202 | 45.824 | 0 | 0 |
Receivables | 47.564 | 22.648 | 68.507 | 31.757 | 34.625 | 58.116 | 65.354 | 119.697 | 102.062 | 311.439 |
Cash | 30.462 | 27.641 | -829 | 5.883 | 15.066 | -5.857 | 4.082 | 1.718 | -57.170 | -22.570 |
Shareholders Funds | 1.855 | 45.256 | -7.440 | 12.400 | 40.382 | 2.673 | 9.308 | 18.502 | -36.923 | 11.143 |
Social Capital | 45 | 112 | 111 | 109 | 107 | 105 | 103 | 101 | 101 | 101 |
Debts | 93.850 | 30.662 | 99.722 | 41.480 | 42.182 | 64.514 | 99.279 | 187.685 | 175.042 | 396.284 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "4329 - 4329" | |||||||||
CAEN Financial Year |
4329
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Izoprim S.r.l.